90065-66-0

Usage

Uses

Used in Pharmaceutical Development:
1-Methyl-7-deazaguanine is utilized as a pharmaceutical compound due to its unique structure and properties, which may offer therapeutic benefits in various medical applications.
Used in Enzyme and Coenzyme Components:
In the microorganism industry, 1-Methyl-7-deazaguanine serves as a component of enzymes and coenzymes, such as the enzyme queuine tRNA-ribosyltransferase and the coenzyme queuine, playing a crucial role in their functions.
Used in Nucleic Acid-based Technologies:
1-Methyl-7-deazaguanine is employed in the development of new nucleic acid-based technologies, leveraging its distinct chemical properties to enhance or create innovative applications in molecular biology and genetic research.

Upstream product

• 90065-71-7 2-amino-4-chloro-7-methyl-7H-pyrrolo<2,3-d>pyrimidine 
• 107-20-0 2-chloroethanal 
• 54004-20-5 2-amino-6-(methylamino)pyrimidin-4(3H)-one 
• 84955-31-7 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 54004-20-5 2-amino-4-hydroxy-6-methylaminopyrimidine 
• 90065-74-0 2-amino-4-<(2-hydroxyethyl)thio>-7-methyl-7H-pyrrolo<2,3-d>pyrimidine 
• 84955-33-9 2-amino-4-methoxy-7-methyl-7H-pyrrolo<2,3-d>pyrimidine 

Relevant academic research and scientific papers

Isomeric N-methyl-7-deazaguanines: Synthesis, structural assignment, and inhibitory activity on xanthine oxidase

The N-methyl isomers of 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one1 (2a) have been synthesized regiospecifically and their structures assigned. The 3-methyl thylcompound was obtained by alkylation of the parent chromophore 2a with dim

HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN

The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).

Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor

A new class of pyrrolo[2,3-d]pyrimidin-4-one corticotropin-releasing factor 1 (CRF1) receptor antagonists has been designed and synthesized. In general, reported CRF1 receptor antagonists possess a sp 2-nitrogen atom as hy

CYCLIC COMPOUNDS

There is provided a CRF receptor antagonist comprising a compound of the formula (I): A-W-Ar wherein, A is a group represented by the formula (A1) or (A2) (wherein, ring Aa is a 5-or 6-membered ring which may be further substituted; ring Ab is a 5-or 6-membered ring which may be further substituted; ring Ac is a 5- or 6-membered ring which may be substituted; R1 is optionally substituted alkyl, substituted amino, substituted hydroxy, etc.; X is carbonyl, -O-, -S-, etc.; Y1, Y2 and Q are independently optionally substituted carbon or nitrogen; … is a single or double bond); W is a bond, optionally substituted methylene, optionally substituted imino, -O-, -S-, etc.; Ar is optionally substituted aryl or optionally substituted heteroaryl; or a salt thereof or a prodrug thereof.

The synthesis and determination of acidic ionization constants of certain 5-substituted 2-aminopyrrolo[2,3-d]pyrimidin-4-ones and methylated analogs

The acidic ionization constants were determined for a series of 5-substituted 2-aminopyrrolo[2,3-dl-pyrimidin-4-ones and N-3- and N-7-methylated analogs thereof. The syntheses of the methylated analogs are also described.